Company: Wyeth
2007 Sales: $2.2 billion
Market share: 3%
CAGR: 38.4%
What they have: Wyeth's top-selling biologic is Enbrel, which it markets with Amgen. The monoclonal antibody is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and chronic moderate to severe plaque psoriasis.
What to look for: Bapineuzumab--currently in Phase III development--is a humanized monoclonal antibody being investigated for the treatment of Alzheimer's disease and possibly glaucoma.
Links:
[1] http://www.fiercebiotech.com/special-reports/schering-plough-biotech-marketshare-report
[2] http://www.fiercebiotech.com/special-reports/biotech-marketshare-report